Han Yaqian, Li Shizhen, Oyang Linda, Cui Shiwen, Zhang Wenlong, Yang Wenjuan, Peng Mingjing, Tan Shiming, Xia Longzheng, Lin Jinguan, Xu Xuemeng, Wu Nayiyuan, Jiang Xianjie, Peng Qiu, Tang Yanyan, Luo Xia, Liao Qianjin, Zhou Yujuan
The Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Key Laboratory of Cancer Metabolism Changsha, Central South University, Hunan Cancer Hospital, 283 Tongzipo Road, Changsha, Changsha, Hunan, 410013, China.
Department of Oncology, Hunan Provincial People's Hospital (The First- Affiliated Hospital of Hunan Normal University), 61 Jiefang West Road, Changsha, Hunan, 410005, China.
Cell Oncol (Dordr). 2025 Jul 2. doi: 10.1007/s13402-025-01086-1.
Abnormal post-translational modifications (PTMs) play a crucial role in tumor initiation and progression. However, the mechanisms by which lncRNAs, as emerging epigenetic regulators, mediate PTMs remain largely unexplored. This review provides a comprehensive summary of the latest research on the interplay between lncRNA-mediated PTMs and tumorigenesis. We delve into the molecular mechanisms underlying these interactions, focusing on how lncRNAs regulate PTMs to influence tumor progression. We place particular emphasis on the lncRNA-mediated PTMs as a driver of therapeutic resistance, shedding light on its potential as a novel target for cancer intervention. Furthermore, we highlight the therapeutic potential of targeting lncRNA-PTM networks, emphasizing novel RNA-based strategies and their clinical relevance in cancer treatment. We believe that an in-depth understanding of lncRNA-mediated PTMs could uncover novel therapeutic targets, paving the way for innovative approaches in cancer diagnosis and treatment.
异常的翻译后修饰（PTMs）在肿瘤的发生和发展中起着关键作用。然而，作为新兴的表观遗传调节因子，长链非编码RNA（lncRNAs）介导PTMs的机制在很大程度上仍未被探索。本综述全面总结了lncRNA介导的PTMs与肿瘤发生之间相互作用的最新研究。我们深入探讨了这些相互作用的分子机制，重点关注lncRNAs如何调节PTMs以影响肿瘤进展。我们特别强调lncRNA介导的PTMs作为治疗抗性驱动因素的作用，揭示其作为癌症干预新靶点的潜力。此外，我们强调靶向lncRNA-PTM网络的治疗潜力，强调基于RNA的新策略及其在癌症治疗中的临床相关性。我们相信，深入了解lncRNA介导的PTMs可以发现新的治疗靶点，为癌症诊断和治疗的创新方法铺平道路。
